Health
Nanoparticle based shot could boost efficacy, accelerate production of seasonal flu vaccines – BioPharma-Reporter.com
Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein…
Key to the vaccine’s success is a liposome the developers created called cobalt-porphyrin-phospholipid, or CoPoP. They are tiny spherical sacs, which are small enough to be considered nanoparticles, and they form the backbone of the vaccine platform.
Described in a study published on May 24 by the Proceedings of the National Academy of Science, the experimental vaccine has reportedly proven effective in preclinical studies.
The results are very encouraging, says the study’s senior author, Jonathan…
-
General20 hours agoWondering about winter | The Spectator Australia
-
Noosa News18 hours agoJane Bunn weather: Cyclone Errol forms as effects of Alfred still felt across Queensland
-
Business23 hours agoAre Domain Holdings shares undervalued?
-
Business21 hours agoWiseTech shares lift off amid agreement with founder Richard White